Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bergeron, R.
Right arrow Articles by Shulman, G. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergeron, R.
Right arrow Articles by Shulman, G. I.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes 50:1076-1082, 2001
© 2001 by the American Diabetes Association, Inc.

Effect of 5-Aminoimidazole-4-Carboxamide-1-ß-D-Ribofuranoside Infusion on In Vivo Glucose and Lipid Metabolism in Lean and Obese Zucker Rats

Raynald Bergeron1, Stephen F. Previs1, Gary W. Cline1, Pascale Perret1, Raymond R. Russell III1, Lawrence H. Young1, and Gerald I. Shulman1,2,3

1 Internal Medicine and
2 Cellular and Molecular Physiology, and the
3 Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut. Current address for S.F.P. is the Department of Nutrition, Case Western Reserve University School of Medicine, Cleveland, OH 44106-4951.

Activation of AMP-activated protein kinase (AMPK) with 5-aminoimidazole-4-carboxamide-1-ß-D-ribofuranoside (AICAR) increases glucose transport in skeletal muscle via an insulin-independent pathway. To examine the effects of AMPK activation on skeletal muscle glucose transport activity and whole-body carbohydrate and lipid metabolism in an insulin-resistant rat model, awake obese Zucker fa/fa rats (n = 26) and their lean (n = 23) littermates were infused for 90 min with AICAR, insulin, or saline. The insulin infusion rate (4 mU · kg-1 · min-1) was selected to match the glucose requirements during AICAR (bolus, 100 mg/kg; constant, 10 mg · kg-1 · min-1) isoglycemic clamps in the lean rats. The effects of these identical AICAR and insulin infusion rates were then examined in the obese Zucker rats. AICAR infusion increased muscle AMPK activity more than fivefold (P < 0.01 vs. control and insulin) in both lean and obese rats. Plasma triglycerides, fatty acid concentrations, and glycerol turnover, as assessed by [2-13C]glycerol, were all decreased in both lean and obese rats infused with AICAR (P < 0.05 vs. basal), whereas insulin had no effect on these parameters in the obese rats. Endogenous glucose production rates, measured by [U-13C]glucose, were suppressed by >50% during AICAR and insulin infusions in both lean and obese rats (P < 0.05 vs. basal). In lean rats, rates of whole-body glucose disposal increased by more than twofold (P < 0.05 vs. basal) during both AICAR and insulin infusion; [3H]2-deoxy-D-glucose transport activity increased to a similar extent, by >2.2-fold (both P < 0.05 vs. control), in both soleus and red gastrocnemius muscles of lean rats infused with either AICAR or insulin. In the obese Zucker rats, neither AICAR nor insulin stimulated whole-body glucose disposal or soleus muscle glucose transport activity. However, AICAR increased glucose transport activity by ~2.4-fold (P < 0.05 vs. control) in the red gastrocnemius from obese rats, whereas insulin had no effect. In summary, acute infusion of AICAR in an insulin-resistant rat model activates skeletal muscle AMPK and increases glucose transport activity in red gastrocnemius muscle while suppressing endogenous glucose production and lipolysis. Because type 2 diabetes is characterized by diminished rates of insulin-stimulated glucose uptake as well as increased basal rates of endogenous glucose production and lipolysis, these results suggest that AICAR-related compounds may represent a new class of antidiabetic agents.


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. J. Sanders, Z. S. Ali, B. D. Hegarty, R. Heath, M. A. Snowden, and D. Carling
Defining the Mechanism of Activation of AMP-activated Protein Kinase by the Small Molecule A-769662, a Member of the Thienopyridone Family
J. Biol. Chem., November 9, 2007; 282(45): 32539 - 32548.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. Goransson, A. McBride, S. A. Hawley, F. A. Ross, N. Shpiro, M. Foretz, B. Viollet, D. G. Hardie, and K. Sakamoto
Mechanism of Action of A-769662, a Valuable Tool for Activation of AMP-activated Protein Kinase
J. Biol. Chem., November 9, 2007; 282(45): 32549 - 32560.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. J. Cuthbertson, J. A. Babraj, K. J.W. Mustard, M. C. Towler, K. A. Green, H. Wackerhage, G. P. Leese, K. Baar, M. Thomason-Hughes, C. Sutherland, et al.
5-Aminoimidazole-4-Carboxamide 1-{beta}-D-Ribofuranoside Acutely Stimulates Skeletal Muscle 2-Deoxyglucose Uptake in Healthy Men
Diabetes, August 1, 2007; 56(8): 2078 - 2084.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Sriwijitkamol, D. K. Coletta, E. Wajcberg, G. B. Balbontin, S. M. Reyna, J. Barrientes, P. A. Eagan, C. P. Jenkinson, E. Cersosimo, R. A. DeFronzo, et al.
Effect of Acute Exercise on AMPK Signaling in Skeletal Muscle of Subjects With Type 2 Diabetes: A Time-Course and Dose-Response Study
Diabetes, March 1, 2007; 56(3): 836 - 848.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. L. Jacobs, S. Lingrell, J. R. B. Dyck, and D. E. Vance
Inhibition of Hepatic Phosphatidylcholine Synthesis by 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside Is Independent of AMP-activated Protein Kinase Activation
J. Biol. Chem., February 16, 2007; 282(7): 4516 - 4523.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. C. Towler and D. G. Hardie
AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling
Circ. Res., February 16, 2007; 100(3): 328 - 341.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. Fujii, N. Jessen, and L. J. Goodyear
AMP-activated protein kinase and the regulation of glucose transport
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E867 - E877.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Christopher, C. Rantzau, Z.-P. Chen, R. Snow, B. Kemp, and F. P. Alford
Impact of in vivo fatty acid oxidation blockade on glucose turnover and muscle glucose metabolism during low-dose AICAR infusion
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E1131 - E1140.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. P. Kinman, T. Kasumov, K. A. Jobbins, K. R. Thomas, J. E. Adams, L. N. Brunengraber, G. Kutz, W.-U. Brewer, C. R. Roe, and H. Brunengraber
Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats
Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E860 - E866.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. J. Yoon, G. Y. Lee, J.-J. Chung, Y. H. Ahn, S. H. Hong, and J. B. Kim
Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, p38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator-Activated Receptor {alpha}
Diabetes, September 1, 2006; 55(9): 2562 - 2570.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. S. Lee-Young, M. J. Palmer, K. C. Linden, K. LePlastrier, B. J. Canny, M. Hargreaves, G. D. Wadley, B. E. Kemp, and G. K. McConell
Carbohydrate ingestion does not alter skeletal muscle AMPK signaling during exercise in humans
Am J Physiol Endocrinol Metab, September 1, 2006; 291(3): E566 - E573.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
B. Viollet, M. Foretz, B. Guigas, S. Horman, R. Dentin, L. Bertrand, L. Hue, and F. Andreelli
Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders
J. Physiol., July 1, 2006; 574(1): 41 - 53.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
N. K. LeBrasseur, M. Kelly, T.-S. Tsao, S. R. Farmer, A. K. Saha, N. B. Ruderman, and E. Tomas
Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues
Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E175 - E181.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
F. Andreelli, M. Foretz, C. Knauf, P. D. Cani, C. Perrin, M. A. Iglesias, B. Pillot, A. Bado, F. Tronche, G. Mithieux, et al.
Liver Adenosine Monophosphate-Activated Kinase-{alpha}2 Catalytic Subunit Is a Key Target for the Control of Hepatic Glucose Production by Adiponectin and Leptin But Not Insulin
Endocrinology, May 1, 2006; 147(5): 2432 - 2441.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. Sriwijitkamol, J. L. Ivy, C. Christ-Roberts, R. A. DeFronzo, L. J. Mandarino, and N. Musi
LKB1-AMPK signaling in muscle from obese insulin-resistant Zucker rats and effects of training
Am J Physiol Endocrinol Metab, May 1, 2006; 290(5): E925 - E932.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B. Guigas, L. Bertrand, N. Taleux, M. Foretz, N. Wiernsperger, D. Vertommen, F. Andreelli, B. Viollet, and L. Hue
5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside and Metformin Inhibit Hepatic Glucose Phosphorylation by an AMP-Activated Protein Kinase-Independent Effect on Glucokinase Translocation.
Diabetes, April 1, 2006; 55(4): 865 - 874.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
R. C. Camacho, D. B. Lacy, F. D. James, E. P. Donahue, and D. H. Wasserman
5-Aminoimidazole-4-carboxamide-1-{beta}-D-ribofuranoside renders glucose output by the liver of the dog insensitive to a pharmacological increment in insulin
Am J Physiol Endocrinol Metab, December 1, 2005; 289(6): E1039 - E1043.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Daval, F. Diot-Dupuy, R. Bazin, I. Hainault, B. Viollet, S. Vaulont, E. Hajduch, P. Ferre, and F. Foufelle
Anti-lipolytic Action of AMP-activated Protein Kinase in Rodent Adipocytes
J. Biol. Chem., July 1, 2005; 280(26): 25250 - 25257.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. D. Erion, P. D. van Poelje, Q. Dang, S. R. Kasibhatla, S. C. Potter, M. R. Reddy, K. R. Reddy, T. Jiang, and W. N. Lipscomb
MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes
PNAS, May 31, 2005; 102(22): 7970 - 7975.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Foretz, N. Ancellin, F. Andreelli, Y. Saintillan, P. Grondin, A. Kahn, B. Thorens, S. Vaulont, and B. Viollet
Short-Term Overexpression of a Constitutively Active Form of AMP-Activated Protein Kinase in the Liver Leads to Mild Hypoglycemia and Fatty Liver
Diabetes, May 1, 2005; 54(5): 1331 - 1339.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. R. Pencek, J. Shearer, R. C. Camacho, F. D. James, D. B. Lacy, P. T. Fueger, E. P. Donahue, W. Snead, and D. H. Wasserman
5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside Causes Acute Hepatic Insulin Resistance In Vivo
Diabetes, February 1, 2005; 54(2): 355 - 360.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. C. Camacho, R. R. Pencek, D. B. Lacy, F. D. James, E. P. Donahue, and D. H. Wasserman
Portal Venous 5-Aminoimidazole-4-Carboxamide-1-{beta}-D-Ribofuranoside Infusion Overcomes Hyperinsulinemic Suppression of Endogenous Glucose Output
Diabetes, February 1, 2005; 54(2): 373 - 382.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
M. E. Hafidi, I. Perez, J. Zamora, V. Soto, G. Carvajal-Sandoval, and G. Banos
Glycine intake decreases plasma free fatty acids, adipose cell size, and blood pressure in sucrose-fed rats
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2004; 287(6): R1387 - R1393.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. L.M. Coort, D. M. Hasselbaink, D. P.Y. Koonen, J. Willems, W. A. Coumans, A. Chabowski, G. J. van der Vusse, A. Bonen, J. F.C. Glatz, and J. J.F.P. Luiken
Enhanced Sarcolemmal FAT/CD36 Content and Triacylglycerol Storage in Cardiac Myocytes From Obese Zucker Rats
Diabetes, July 1, 2004; 53(7): 1655 - 1663.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
K. Hojlund, K. J. Mustard, P. Staehr, D. G. Hardie, H. Beck-Nielsen, E. A. Richter, and J. F. P. Wojtaszewski
AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes
Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E239 - E244.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Yamamoto, H. Hirose, I. Saito, K. Nishikai, and T. Saruta
Adiponectin, an Adipocyte-Derived Protein, Predicts Future Insulin Resistance: Two-Year Follow-Up Study in Japanese Population
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 87 - 90.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
D. G. Hardie
Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status
Endocrinology, December 1, 2003; 144(12): 5179 - 5183.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Zong, J. M. Ren, L. H. Young, M. Pypaert, J. Mu, M. J. Birnbaum, and G. I. Shulman
AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation
PNAS, December 10, 2002; 99(25): 15983 - 15987.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
J. Stoppani, A. L. Hildebrandt, K. Sakamoto, D. Cameron-Smith, L. J. Goodyear, and P. D. Neufer
AMP-activated protein kinase activates transcription of the UCP3 and HKII genes in rat skeletal muscle
Am J Physiol Endocrinol Metab, December 1, 2002; 283(6): E1239 - E1248.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G. S. Olsen and B. F. Hansen
AMP kinase activation ameliorates insulin resistance induced by free fatty acids in rat skeletal muscle
Am J Physiol Endocrinol Metab, November 1, 2002; 283(5): E965 - E970.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
T. K. T. Lam, H. Yoshii, C. A. Haber, E. Bogdanovic, L. Lam, I. G. Fantus, and A. Giacca
Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta
Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E682 - E691.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. A. Iglesias, J.-M. Ye, G. Frangioudakis, A. K. Saha, E. Tomas, N. B. Ruderman, G. J. Cooney, and E. W. Kraegen
AICAR Administration Causes an Apparent Enhancement of Muscle and Liver Insulin Action in Insulin-Resistant High-Fat-Fed Rats
Diabetes, October 1, 2002; 51(10): 2886 - 2894.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B. R. Barnes, J. W. Ryder, T. L. Steiler, L. G.D. Fryer, D. Carling, and J. R. Zierath
Isoform-Specific Regulation of 5' AMP-Activated Protein Kinase in Skeletal Muscle From Obese Zucker (fa/fa) Rats in Response to Contraction
Diabetes, September 1, 2002; 51(9): 2703 - 2708.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
J. R. Zierath
Exercise Effects of Muscle Insulin Signaling and Action: Invited Review: Exercise training-induced changes in insulin signaling in skeletal muscle
J Appl Physiol, August 1, 2002; 93(2): 773 - 781.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
N. Musi, M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, G. Zhou, J. M. Williamson, O. Ljunqvist, S. Efendic, et al.
Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes
Diabetes, July 1, 2002; 51(7): 2074 - 2081.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
E. S. Buhl, N. Jessen, R. Pold, T. Ledet, A. Flyvbjerg, S. B. Pedersen, O. Pedersen, O. Schmitz, and S. Lund
Long-Term AICAR Administration Reduces Metabolic Disturbances and Lowers Blood Pressure in Rats Displaying Features of the Insulin Resistance Syndrome
Diabetes, July 1, 2002; 51(7): 2199 - 2206.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. H. Clerk, S. Rattigan, and M. G. Clark
Lipid Infusion Impairs Physiologic Insulin-Mediated Capillary Recruitment and Muscle Glucose Uptake In Vivo
Diabetes, April 1, 2002; 51(4): 1138 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
W. G. Aschenbach, M. F. Hirshman, N. Fujii, K. Sakamoto, K. F. Howlett, and L. J. Goodyear
Effect of AICAR Treatment on Glycogen Metabolism in Skeletal Muscle
Diabetes, March 1, 2002; 51(3): 567 - 573.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2001 by the American Diabetes Association.